Literature DB >> 23702511

Identification and characterisation of mutations associated with von Willebrand disease in a Turkish patient cohort.

Daniel J Hampshire1, Adel M Abuzenadah, Ashley Cartwright, Nawal S Al-Shammari, Rachael E Coyle, Michaela Eckert, Ahlam M Al-Buhairan, Sarah L Messenger, Ulrich Budde, Türkiz Gürsel, Jørgen Ingerslev, Ian R Peake, Anne C Goodeve.   

Abstract

Several cohort studies have investigated the molecular basis of von Willebrand disease (VWD); however, these have mostly focused on European and North American populations. This study aimed to investigate mutation spectrum in 26 index cases (IC) from Turkey diagnosed with all three VWD types, the majority (73%) with parents who were knowingly related. IC were screened for mutations using multiplex ligation-dependent probe amplification and analysis of all von Willebrand factor gene (VWF) exons and exon/intron boundaries. Selected missense mutations were expressed in vitro. Candidate VWF mutations were identified in 25 of 26 IC and included propeptide missense mutations in four IC (two resulting in type 1 and two in recessive 2A), all influencing VWF expression in vitro. Four missense mutations, a nonsense mutation and a small in-frame insertion resulting in type 2A were also identified. Of 15 type 3 VWD IC, 13 were homozygous and two compound heterozygous for 14 candidate mutations predicted to result in lack of expression and two propeptide missense changes. Identification of intronic breakpoints of an exon 17-18 deletion suggested that the mutation resulted from non-homologous end joining. This study provides further insight into the pathogenesis of VWD in a population with a high degree of consanguineous partnerships.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23702511      PMCID: PMC4213552          DOI: 10.1160/TH13-02-0135

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  48 in total

1.  Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral.

Authors:  S V Tavtigian; A M Deffenbaugh; L Yin; T Judkins; T Scholl; P B Samollow; D de Silva; A Zharkikh; A Thomas
Journal:  J Med Genet       Date:  2005-07-13       Impact factor: 6.318

2.  Effect of the VWF promoter (GT)n repeat and single-nucleotide polymorphism c.-2527G>A on circulating von Willebrand factor levels under normal conditions.

Authors:  N Hickson; D Hampshire; G Castaman; J Eikenboom; F Rodeghiero; I Peake; A Goodeve
Journal:  J Thromb Haemost       Date:  2011-03       Impact factor: 5.824

3.  Large experience with a factor VIII binding assay of plasma von Willebrand factor using commercial reagents.

Authors:  Claudine Caron; Claudine Mazurier; Jenny Goudemand
Journal:  Br J Haematol       Date:  2002-06       Impact factor: 6.998

4.  Molecular defects in type 3 von Willebrand disease: updated results from 40 multiethnic patients.

Authors:  Luciano Baronciani; Giovanna Cozzi; Maria Teresa Canciani; Flora Peyvandi; Alok Srivastava; Augusto B Federici; Pier Mannuccio Mannucci
Journal:  Blood Cells Mol Dis       Date:  2003 May-Jun       Impact factor: 3.039

5.  Prevalence of von Willebrand disease in children: a multiethnic study.

Authors:  E J Werner; E H Broxson; E L Tucker; D S Giroux; J Shults; T C Abshire
Journal:  J Pediatr       Date:  1993-12       Impact factor: 4.406

6.  The frequency of consanguineous marriage in eastern Turkey.

Authors:  S Akbayram; N Sari; C Akgün; M Doğan; O Tuncer; H Caksen; A F Oner
Journal:  Genet Couns       Date:  2009

7.  Analysis of intracellular storage and regulated secretion of 3 von Willebrand disease-causing variants of von Willebrand factor.

Authors:  Grégoire Michaux; Lindsay J Hewlett; Sarah L Messenger; Anne C Goodeve; Ian R Peake; Martina E Daly; Daniel F Cutler
Journal:  Blood       Date:  2003-06-05       Impact factor: 22.113

8.  Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium.

Authors:  Nicholas L Smith; Ming-Huei Chen; Abbas Dehghan; David P Strachan; Saonli Basu; Nicole Soranzo; Caroline Hayward; Igor Rudan; Maria Sabater-Lleal; Joshua C Bis; Moniek P M de Maat; Ann Rumley; Xiaoxiao Kong; Qiong Yang; Frances M K Williams; Veronique Vitart; Harry Campbell; Anders Mälarstig; Kerri L Wiggins; Cornelia M Van Duijn; Wendy L McArdle; James S Pankow; Andrew D Johnson; Angela Silveira; Barbara McKnight; Andre G Uitterlinden; Nena Aleksic; James B Meigs; Annette Peters; Wolfgang Koenig; Mary Cushman; Sekar Kathiresan; Jerome I Rotter; Edwin G Bovill; Albert Hofman; Eric Boerwinkle; Geoffrey H Tofler; John F Peden; Bruce M Psaty; Frank Leebeek; Aaron R Folsom; Martin G Larson; Timothy D Spector; Alan F Wright; James F Wilson; Anders Hamsten; Thomas Lumley; Jacqueline C M Witteman; Weihong Tang; Christopher J O'Donnell
Journal:  Circulation       Date:  2010-03-15       Impact factor: 29.690

9.  An integrated map of genetic variation from 1,092 human genomes.

Authors:  Goncalo R Abecasis; Adam Auton; Lisa D Brooks; Mark A DePristo; Richard M Durbin; Robert E Handsaker; Hyun Min Kang; Gabor T Marth; Gil A McVean
Journal:  Nature       Date:  2012-11-01       Impact factor: 49.962

10.  Mechanisms for human genomic rearrangements.

Authors:  Wenli Gu; Feng Zhang; James R Lupski
Journal:  Pathogenetics       Date:  2008-11-03
View more
  6 in total

1.  Characterization of large in-frame von Willebrand factor deletions highlights differing pathogenic mechanisms.

Authors:  Ashley Cartwright; Simon J Webster; Annika de Jong; Richard J Dirven; Lisa D S Bloomer; Ahlam M Al-Buhairan; Ulrich Budde; Christer Halldén; David Habart; Jenny Goudemand; Ian R Peake; Jeroen C J Eikenboom; Anne C Goodeve; Daniel J Hampshire
Journal:  Blood Adv       Date:  2020-07-14

2.  In silico analysis highlights the copy number variation mechanism responsible for the historically reported VWF exon 42 deletion.

Authors:  A Cartwright; I R Peake; A C Goodeve; D J Hampshire
Journal:  Haemophilia       Date:  2016-08-01       Impact factor: 4.287

3.  p.P2063S: a neutral VWF variant masquerading as a mutation.

Authors:  Daniel J Hampshire; Anne C Goodeve
Journal:  Ann Hematol       Date:  2013-06-18       Impact factor: 3.673

4.  ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease.

Authors:  Paula D James; Nathan T Connell; Barbara Ameer; Jorge Di Paola; Jeroen Eikenboom; Nicolas Giraud; Sandra Haberichter; Vicki Jacobs-Pratt; Barbara Konkle; Claire McLintock; Simon McRae; Robert R Montgomery; James S O'Donnell; Nikole Scappe; Robert Sidonio; Veronica H Flood; Nedaa Husainat; Mohamad A Kalot; Reem A Mustafa
Journal:  Blood Adv       Date:  2021-01-12

5.  Genotypes of European and Iranian patients with type 3 von Willebrand disease enrolled in 3WINTERS-IPS.

Authors:  Luciano Baronciani; Ian Peake; Reinhard Schneppenheim; Anne Goodeve; Minoo Ahmadinejad; Zahra Badiee; Mohammad-Reza Baghaipour; Olga Benitez; Imre Bodó; Ulrich Budde; Andrea Cairo; Giancarlo Castaman; Peyman Eshghi; Jenny Goudemand; Wolf Hassenpflug; Hamid Hoorfar; Mehran Karimi; Bijan Keikhaei; Riitta Lassila; Frank W G Leebeek; Maria Fernanda Lopez Fernandez; Pier Mannuccio Mannucci; Renato Marino; Nikolas Nikšić; Florian Oyen; Cristina Santoro; Andreas Tiede; Gholamreza Toogeh; Alberto Tosetto; Marc Trossaert; Eva M K Zetterberg; Jeroen Eikenboom; Augusto B Federici; Flora Peyvandi
Journal:  Blood Adv       Date:  2021-08-10

6.  Resolving Differential Diagnostic Problems in von Willebrand Disease, in Fibrinogen Disorders, in Prekallikrein Deficiency and in Hereditary Hemorrhagic Telangiectasia by Next-Generation Sequencing.

Authors:  Réka Gindele; Adrienne Kerényi; Judit Kállai; György Pfliegler; Ágota Schlammadinger; István Szegedi; Tamás Major; Zsuzsanna Szabó; Zsuzsa Bagoly; Csongor Kiss; János Kappelmayer; Zsuzsanna Bereczky
Journal:  Life (Basel)       Date:  2021-03-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.